DMB-I in the Treatment of Alzheimer Type Dementia

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

January 13, 2025

Study Completion Date

January 31, 2025

Conditions
Alzheimer DiseaseDementia of Alzheimer Type
Interventions
DRUG

DMB-I (Dimebon)

20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)

OTHER

Placebo

20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)

Trial Locations (7)

117997

"Federal State Budgetary Institution Federal center for brain and neurotechnologies of the Federal Medical and Biological Agency (FSBI FCBN of Russia's FMBA)", Moscow

119991

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow

150000

"Centre of evidence-based medicine LLC", Yaroslavl

188820

State public healthcare institution Leningrad regional psychoneurologic dispensary, Roshchino

197706

"Saint Petersburg State budgetary healthcare institution City Hospital № 40 of Kurortniy district", Saint Petersburg

344082

"Medical Center Nova Vita", Rostov-on-Don

420101

"State autonomous healthcare institution Transregional Clinical Diagnostic Center", Kazan'

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bigespas LTD

INDUSTRY